Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

IBA – ACQUISITION OF OWN SHARES
By: GlobenewsWire - 23 Jul 2021Back to overview list

Immediate Release – July 23rd, 2021

Louvain-la-Neuve, Belgium, July 23rd, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on June 29th, 2021.

Under this program, IBA has requested a financial intermediary to repurchase up to 250.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until December 30th, 2021, effective as from June 30th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 45.251 IBA shares on Euronext Brussels in the period from July 16th, 2021 up to and including July 22nd, 2021, as follows:

These transactions include the purchase of several blocks of shares on the central order book of Euronext Brussels (XBRU):

  • On July 19th at 9.39 AM: 22.000 shares at a price of 16,48 EUR/share;
  • On July 19th at 10.01 AM: 10.000 shares at a price of 16,46 EUR/share;

The total number of shares purchased under this program therefore amounts to 100.797. As a result, IBA SA currently holds 921.669 treasury shares (directly and indirectly through its subsidiary IBA Investments SCRL), representing 3,06% of its share capital.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

Contact person

IBA
Christian Matton,
Chief Legal Officer
shareholderrelations@iba-group.com

Attachment


Related companies:IBA - Ion Beam Application
Copyright 2021 GlobenewsWire Back to overview list
to the top ↑